TLR Agonists as Adjuvants for Cancer Vaccines.

Li, Ji-Kun; Balic, Jesse J; Yu, Liang; Jenkins, Brendan

Li, Ji-Kun; Balic, Jesse J; Yu, Liang; Jenkins, Brendan.

Afiliación

Li JK; Department of General Surgery, Shanghai Jiao Tong University Affiliated First People's Hospital, Shanghai Jiao Tong University, Shanghai, 200080, China.
Balic JJ; Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, 27-31 Wright Street, Clayton, 3168, VIC, Australia.
Yu L; Department of Molecular Translational Science, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, 3800, VIC, Australia.
Jenkins B; Department of General Surgery, Shanghai Jiao Tong University Affiliated First People's Hospital, Shanghai Jiao Tong University, Shanghai, 200080, China. Liang.yu@hudson.org.au.

Adv Exp Med Biol ; 1024: 195-212, 2017.

Article en En | MEDLINE | ID: mdl-28921471

Asunto(s)

Adyuvantes Inmunológicos; Vacunas contra el Cáncer/inmunología; Neoplasias/prevención & control; Receptores Toll-Like/agonistas; Humanos; Receptores Toll-Like/inmunología

Palabras clave

Adjuvant; Agonist; Clinical trial; Toll-like receptor

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Adyuvantes Inmunológicos / Vacunas contra el Cáncer / Receptores Toll-Like / Neoplasias Límite: Humans Idioma: En Revista: Adv Exp Med Biol Año: 2017 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google